ALPMY News and Press, Astellas Pharma Inc. ADR From 10/05/23

2023-10-05 07:30:43 ET More on Merck Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying US government to stop distributing Merck's CO...

2023-09-22 06:49:12 ET More on Merck Seeking Alpha’s Quant Rating on Merck Historical earnings data for Merck Financial information for Merck Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend St...

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial PR Newswire – Trial results to ...

Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA) PR Newswire GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people...

2023-09-19 09:29:45 ET More on Astellas, Apellis, etc. Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Wells Fargo ups Apellis to overweight, stock climbs ...

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated w...

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize PR Newswire Awardees win a year of access to a prestigious life-science incubator in San Francisco, CA and to Astellas expertise to further their research Award he...

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society PR Newswire Pooled analyses from pivotal Phase 3 SKYLIGHT™ studies provide new insights into fezolinetant for the treatment of moderate to severe VMS due to m...

2023-09-14 04:51:56 ET Astellas Pharma ( OTCPK:ALPMY ) intends to build a new facility, at an approximate cost of €330M in Tralee, Co. Kerry. Ireland. This investment will expand capacity and capabilities for aseptic drug products, reinforce stable production...

Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland PR Newswire - Investment will build capabilities to supply the Astellas global market and accelerate the development and commercialisation of innovative medicines ...